Aurobindo Pharma’s Subsidiary CuraTeQ Secures UK Approval for Bevacizumab Biosimilar

SCG Cell Therapy Partners with A*STAR BTI and NATi to Advance RNA-Based Therapeutics

Korea's National Bio Big Data Project: Advancing Precision Medicine with Macrogen and Illumina

GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Home
/
update
/
details

Pfizer Promotes BRAF Mutation Testing in Lung Cancer to Expand Braftovi Market

NextEdge Admin

17 Sep 2024

2 min 15 sec

Pfizer is working to increase awareness among doctors about testing for a rare lung cancer mutation, aiming to boost the use of its drug Braftovi, which it hopes will become the standard of care. At a recent conference, the company presented three-year data from a Phase 2 study on patients with BRAF V600E-mutant metastatic non-small cell lung cancer. Those treated with Braftovi, in combination with another Pfizer drug, Mektovi, had a median progression-free survival of over two-and-a-half years. This suggests the treatment can significantly delay the worsening of cancer.

Chris Boshoff, Pfizer's Chief Oncology Officer, stated that the data supports Braftovi as a standard treatment for this patient group. Approximately 2% to 3% of lung cancer patients have the BRAF mutation. Currently, the standard of care includes immunotherapy and chemotherapy, but fewer than 50% of U.S. lung cancer patients are tested for the mutation, with even lower rates globally. Boshoff emphasized that testing for BRAF mutations could be done through a simple blood test, covered by insurance in the U.S.

Pfizer sold nearly $400 million worth of Braftovi and Mektovi last year. The company also sees potential growth in colorectal cancer, where BRAF mutations are present in 10% of cases, with data from a late-stage study expected by year-end. Pfizer is focusing on global efforts to encourage testing and educate healthcare professionals, patients, and advocacy groups.